The frequency of eye injections for age-related macular degeneration (AMD) is one of the most significant concerns for patients beginning treatment for the “wet” form of the disease. In the United Kingdom, the schedule for these injections is not a one-size-fits-all approach but is instead a highly personalised clinical journey. The goal of treatment is to maintain a “dry” macula by preventing the leakage of fluid and blood from abnormal vessels, which requires a strategic balance of medication and monitoring. While the thought of regular procedures can be intimidating, the structured pathways used by the NHS are designed to maximise sight preservation while gradually reducing the “treatment burden” on the patient. Understanding the different phases of this schedule, from the intensive start to the long-term maintenance, is essential for managing expectations and ensuring the best possible visual outcome.
What We’ll Discuss in This Article
- The standard “loading phase” required for all new wet AMD patients.
- How the “Treat and Extend” pathway determines your unique injection gaps.
- Comparing the typical frequencies for medications like Lucentis, Eylea, and Vabysmo.
- The role of the maintenance phase in preventing the return of fluid.
- Factors that can cause a specialist to shorten or lengthen your schedule.
- Why regular OCT scans are used at every visit to guide the next injection.
- The long-term perspective: How many years of treatment might be expected.
The initial loading phase: Setting the foundation
When a person is first diagnosed with wet AMD in a UK hospital clinic, the primary objective is to gain control over the active leakage as quickly as possible. This is achieved through what is known as the “loading phase” or “induction phase.” During this period, the patient receives a series of injections at fixed, frequent intervals to ensure the concentration of the medication in the eye reaches an effective level.
For most patients, the loading phase consists of three or four injections, administered exactly four weeks apart. This monthly schedule is critical because it takes time for the anti-VEGF medication to fully “starve” the abnormal blood vessels and allow the trapped fluid to be reabsorbed by the retina. Missing an appointment during this initial phase can allow the leakage to continue, leading to permanent scarring before the treatment has a chance to work. Once the specialist confirms that the macula is “dry” or stable on an OCT scan following this phase, they can begin to discuss extending the time between visits. You can find more information on the initial steps of AMD treatment through the official NHS guidance.
The maintenance phase and treat and extend pathway
Once the initial loading phase has successfully stabilised the eye, the clinical focus shifts to the maintenance phase. In the United Kingdom, the preferred method for managing this is the “Treat and Extend” pathway. This protocol is designed to find the longest possible gap between injections that keeps the eye free of fluid. It is a proactive approach that aims to prevent a “flare-up” rather than waiting for vision to decline before giving another dose.
Under this pathway, a patient receives an injection at every visit, but the time between visits is adjusted based on the results of the retinal scans. If the eye is dry and stable at a four-week interval, the specialist will “extend” the next appointment to six weeks. If it remains dry at six weeks, the next may be at eight weeks, and so on. The intervals are usually increased by two weeks at a time. This method ensures the patient is always protected by the medication while gradually reducing the number of trips to the hospital. If fluid reappears, the interval is immediately shortened to bring the condition back under control. This personalised strategy is a cornerstone of the NICE guidance on managing macular conditions.
Comparing different medications and dosing schedules
The frequency of injections can also be influenced by the specific type of medication being used. In recent years, newer drugs have been introduced to the NHS that are designed to last longer in the eye, potentially allowing for much longer gaps between treatments.
- Ranibizumab (Lucentis): One of the first licensed anti-VEGF drugs, it often requires more frequent dosing, sometimes remaining on a four- or six-week schedule for an extended period.
- Aflibercept (Eylea 2mg): This is a very common choice in the UK and often allows for an average interval of eight weeks, though it can be extended up to twelve weeks in stable patients.
- Aflibercept High Dose (Eylea 8mg): A newer, more concentrated version that is designed to provide longer lasting control, with some patients moving to 12 or even 16-week intervals.
- Faricimab (Vabysmo): This is a “dual-action” drug that blocks two different proteins involved in vessel growth. In many UK clinics, it is showing great success in allowing patients to go 12 or 16 weeks between injections after the loading phase.
The choice of medication is a clinical decision made by your ophthalmologist based on how your eye responds to treatment. Some patients may respond perfectly to one drug but require a switch to another if the fluid remains persistent. The Macular Society provides comprehensive updates on these various medications and their typical dosing schedules.
Factors that influence injection frequency
Several individual factors can influence how often a patient needs an injection. No two eyes are the same, and the “leakiness” of the abnormal blood vessels can vary significantly between people.
- Disease Activity: Some people have very “aggressive” wet AMD that produces fluid quickly, requiring them to stay on a four- or six-week schedule for a long time.
- Response to Medication: Some patients are “super-responders” whose eyes stay dry for months after a single dose, while others may require more frequent “top-ups.”
- Systemic Health: Factors like high blood pressure or smoking can increase the inflammation and vascular stress in the eye, potentially requiring more frequent injections to keep the macula dry.
- Status of the Second Eye: If the other eye is also affected or is at high risk, the specialist may be more conservative with the extension schedule to protect the remaining sight.
In the UK, the Royal College of Ophthalmologists emphasizes that the frequency of treatment should always be a collaborative decision between the clinician and the patient, taking into account both the clinical data and the patient’s lifestyle.
Long-term outlook and pausing treatment
Many patients wonder if they will ever be able to stop having injections. Because wet AMD is a chronic condition, most people require some form of long-term management. However, for a small percentage of patients, the condition may become “inactive” for a very long time. If a patient reaches the maximum extension interval (usually 16 weeks) and remains stable and dry for several consecutive visits, the specialist may discuss a “monitor and extend” or “pause” strategy.
During a pause, the injections are stopped, but the patient must return for regular scans every few months. If any sign of fluid returns, treatment is restarted immediately. It is important to remember that a “pause” is not a “cure.” The condition can become active again at any time, which is why continued monitoring is essential. Most patients in the UK find that a long term, extended schedule provides the best balance of safety and quality of life.
Summary of Injection Frequencies by Phase
| Phase of Treatment | Typical Frequency | Primary Goal |
| Loading Phase | Every 4 weeks (for 3-4 months) | Gain control and dry the macula |
| Extension Phase | Every 6 to 12 weeks | Find the longest stable gap |
| Maintenance Phase | Every 12 to 16 weeks | Prevent the return of fluid |
| Reactive Phase | Shortened (e.g., back to 4-8 weeks) | Address a new “flare-up” of fluid |
| Monitoring Only | Every 3 to 4 months (No injection) | Only if the condition is inactive |
Conclusion
The frequency of AMD eye injections is a highly individualised schedule that starts with a monthly loading phase before moving to a personalised “Treat and Extend” pathway. While some patients may require injections every four to eight weeks, newer medications and stable responses can allow for gaps of up to sixteen weeks. By using regular OCT scans and a proactive dosing strategy, the UK healthcare system aims to keep the macula dry and preserve central vision for the long term. If you experience severe, sudden, or worsening symptoms, call 999 immediately.
Why do I need an injection if my vision feels the same?
Injections are often given to prevent your vision from getting worse; the scan might show fluid that your brain hasn’t noticed yet, and treating it early prevents permanent damage.
Can I switch to a drug that requires fewer injections?
If you are on a frequent schedule, your ophthalmologist may discuss switching you to a longer lasting drug like Vabysmo or high dose Eylea, depending on your eye’s response.
What is the maximum gap allowed between injections?
In most UK clinical protocols, the maximum extension is 12 or 16 weeks, depending on the specific medication and the stability of the eye.
Will I always need an injection at every appointment?
In the “Treat and Extend” pathway, the answer is usually yes; the injection is given to prevent the fluid from returning while you wait for your next scan.
How many injections will I have in the first year?
On average, most patients in the UK receive between six and nine injections during their first year of treatment, including the loading phase.
Can my injections be stopped if I have a poor response?
In rare cases, if the macula has become heavily scarred and injections are no longer providing any benefit, the specialist may discuss stopping treatment to avoid unnecessary procedures.
Does having injections in both eyes mean more frequent visits?
Hospitals usually try to “harmonise” treatment so that you can have both eyes injected on the same day, keeping your number of hospital trips the same.
Authority Snapshot
This article provides a medically grounded overview of the frequency and scheduling of eye injections for wet AMD in the UK. The content was prepared by the Medical Content Team and reviewed by Dr. Rebecca Fernandez, a UK trained physician with experience across internal medicine and acute care. All information presented is strictly aligned with the clinical pathways and “Treat and Extend” protocols established by the NHS and the National Institute for Health and Care Excellence (NICE) to ensure patient safety and accuracy.
